Cargando…

p53 mutation, deprivation and poor prognosis in primary breast cancer

BACKGROUND: The deprivation gap for breast cancer survival remains unexplained by stage at presentation, treatment, or co-morbidities. We hypothesised that p53 mutation might contribute to the impaired outcome observed in patients from deprived communities. METHODS: p53 mutation status was determine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, L, Quinlan, P R, Patten, N, Ashfield, A, Birse-Stewart-Bell, L-J, McCowan, C, Bourdon, J-C, Purdie, C A, Jordan, L B, Dewar, J A, Wu, L, Thompson, A M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837559/ https://www.ncbi.nlm.nih.gov/pubmed/20104224 http://dx.doi.org/10.1038/sj.bjc.6605540

Ejemplares similares

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

p28, A first in class peptide inhibitor of cop1 binding to p53
por: Yamada, T, et al.
Publicado: (2013)

Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut
por: Bach, S P, et al.
Publicado: (2006)

Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition
por: Byrne, N M, et al.
Publicado: (2016)

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
por: Dudley, A C, et al.
Publicado: (2008)

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome
por: Kumar, S R, et al.
Publicado: (2007)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

High cyclin B1 expression is associated with poor survival in breast cancer
por: Aaltonen, K, et al.
Publicado: (2009)

Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma
por: Fiaschetti, G, et al.
Publicado: (2014)

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study
por: Purdie, C A, et al.
Publicado: (2014)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer
por: Abdel-Fatah, T M A, et al.
Publicado: (2014)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

CD44(+)CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis
por: Hurt, E M, et al.
Publicado: (2008)

Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study
por: Purdie, C A, et al.
Publicado: (2010)

Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer
por: Hsu, K-F, et al.
Publicado: (2015)

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases
por: Nagy, E, et al.
Publicado: (2014)

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
por: Canner, J A, et al.
Publicado: (2009)

New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53
por: Sorriento, D, et al.
Publicado: (2015)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Stat3 activation in human endometrial and cervical cancers
por: Chen, C-L, et al.
Publicado: (2007)

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells
por: Li, C, et al.
Publicado: (2005)

Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines
por: Stewart, G D, et al.
Publicado: (2008)

CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling
por: Dubrovska, A, et al.
Publicado: (2012)

An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
por: Lee, H E, et al.
Publicado: (2011)

Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer
por: Soh, C-L, et al.
Publicado: (2014)

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer
por: Tagg, S L C, et al.
Publicado: (2008)

Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells
por: Armstrong, J L, et al.
Publicado: (2005)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
por: Roberts, D L, et al.
Publicado: (2009)

Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
por: Harris, S M, et al.
Publicado: (2005)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo
por: Armstrong, J L, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_g3akvatvn4nj7eqgv1pl9igl7f